Agilon Health (AGL) Q4 2025 earnings review
Painful 2025 Clears the Deck for a 2026 Turnaround
Agilon concluded a brutal 2025 marked by a $391M net loss and massive margin compression resulting from risk adjustment misses and elevated medical costs. Management is now executing a deliberate 'shrink to profitability' strategy, aggressively purging unprofitable contracts and exiting markets to stabilize the business. The narrative has shifted entirely to 2026: guidance projects a massive $296M Adjusted EBITDA improvement, targeting breakeven. While the strategic pivot is logical, execution risk remains exceptionally high given the reliance on assumed CMS rate increases, renegotiated payer economics, and internal cost cuts to bridge the gap.
🐂 Bull Case
The company has reduced its Medicare Part D exposure to less than 15% of membership and exited roughly 84,000 unprofitable members. This fundamentally lowers the volatility of the model.
The $296M EBITDA turnaround in 2026 is backed by tangible drivers: a 9%+ CMS rate bump, improved percentage-of-premium contracts, and $35M in already-executed operating expense reductions.
🐻 Bear Case
Despite structural improvements, gross medical cost trends are expected to remain elevated at ~7.5% in 2026, threatening to eat into the benefits of the CMS rate increases.
The deliberate exit from unprofitable markets means 2026 revenue will decline by roughly 7%. If fixed costs cannot be leveraged efficiently against this smaller base, profitability targets will be missed.
⚖️ Verdict: ⚪
Neutral. The deck is cleared and management has established a credible, mathematics-based bridge to 2026 profitability. However, 'show me' execution is required, as the margin for error against elevated medical cost trends remains razor-thin.
Key Themes
Shrinking to Profitability
Agilon is accelerating its deliberate contraction to save the bottom line. Membership guidance for 2026 reflects exits from approximately 50,000 members tied to unprofitable payor contracts and 34,000 members from previously announced market exits. By shedding low-margin volume, the company is prioritizing unit economics over top-line scale.
Part D De-Risking Exceeds Targets
Management successfully reduced Part D exposure to less than 15% of total membership for 2026. This is a crucial de-risking maneuver that limits the company's exposure to uncontrollable pharmaceutical cost spikes and the impacts of the Inflation Reduction Act, shifting focus squarely back to managing Part C medical costs.
Cost Discipline Realized
SG&A expenses are expected to be approximately $234M in 2026. This reflects a tangible $35M reduction in operating expenses executed during 2025. This leaner overhead structure is a vital component of the bridge to Adjusted EBITDA breakeven on a shrinking revenue base.
Medical Costs Eat the Macro Rate Bump
Management highlights a positive 9%+ CMS final rate update as a major tailwind for 2026. However, they concurrently project gross medical cost trends to remain elevated at 7.5% (7.0% net). This contradicts the narrative of massive structural relief, as the spread between the rate bump and underlying cost inflation remains uncomfortably thin.
ACO REACH Economics Deteriorating
While the core Medicare Advantage business is guided to improve, the ACO model is decelerating. Adjusted EBITDA contribution from the ACO model was $41M in 2025 but is expected to drop by nearly half to $20-$25M in 2026, primarily due to structural CMS model changes and narrower risk corridors.
Macro: Favorable Payor Bids
Agilon expects a 50 bps improvement in 2026 directly from favorable payor bids. Payors have adjusted benefit designs by increasing premiums, deductibles, and maximum out-of-pocket limits, which acts as a structural offset to Agilon's gross medical cost trend.
Enhanced Data Pipeline Deployment
The company's new data pipeline now covers ~85% of membership, improving baseline visibility. This technological infrastructure upgrade is critical for preventing the massive Risk Adjustment Factor (RAF) and Burden of Illness (BOI) forecasting misses that destroyed 2025 profitability.
Other KPIs
Reversing deeply into negative territory compared to +$205M in FY24. The full-year metric was crushed by higher medical utilization and prior period development (RAF forecasting misses) recognized earlier in the year. Q4 alone delivered a -$74M margin, underscoring the necessity of the 2026 contract restructuring.
Excludes $91M associated with unconsolidated ACO entities. The balance sheet provides sufficient liquidity to bridge the gap to 2026 breakeven without immediate dilution, provided the aggressive turnaround metrics are hit.
Guidance
Decelerating. The midpoint of $5.495B implies a 7.4% YoY decline from FY25's $5.93B. This contraction is an intentional byproduct of shedding ~84k unprofitable members to improve the quality of earnings.
Reversing. A massive intended recovery from the -$296M loss in FY25. The midpoint implies breakeven, heavily reliant on the +9% CMS rate update, contract pruning, and realized SG&A savings.
Reversing. The projected jump from -$57M in FY25 to a $325M midpoint indicates management's confidence that exiting bad contracts and capturing higher baseline rates will restore core profitability.
Accelerating sequentially and reversing YoY. Compares to $21M in Q1 2025 and -$142M in Q4 2025, demonstrating that the structural contract improvements effective January 1, 2026, will have an immediate impact.
Key Questions
Medical Cost Trend Visibility
You are guiding to a 7.5% gross medical cost trend for 2026. Given the forecasting failures in 2025, what specific real-time indicators in your new data pipeline give you confidence that this trend won't push into the 8-9% range?
Provider Retention Risk
As Agilon aggressively prunes contracts and shrinks membership by ~84k, what is the risk of alienating high-performing Primary Care Physicians (PCPs) who may suffer network disruption or lost volume?
V28 Risk Adjustment Hurdle
You noted that your clinical pathway initiatives are anticipated to 'exceed the V28 hurdle' for risk adjustment. Can you quantify the specific basis point drag V28 represents in your 2026 baseline?